posted
I had started a board earlier today on investorshub but wantd to share this sweet baby with my allstock friends......
Look at the bottom for all the insider buys... Record earnings....Another one which had some profit takers earlier this morning ......BUT i am in for a long run and I think its time to load up at this level and let it ride....
Should End at least 92 cents and go up for 5 more days....(for short term investors).
If u wanna keep it long like me.......let it settle for some RICE PUDDING style FUN!!! (Its a RICE research company by the way)
Company Reports Record Net Income of $.01 Per Share
Related newsDow Ends Up Nearly 10 As Rally Fizzles'Talladega' Repeats As Box-Office ChampAftermarket Movers: Agilent JumpsBig Movers in the Stock MarketSector Snap: Copper Notches Gains EL DORADO HILLS, Calif., Aug. 15 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ), a world leader in stabilized rice bran research and technology, announced today record financial results and a positive EBITDA for its second quarter and six months ending June 30, 2006.
Total revenues for the three months ended June 30, 2006 were $4,166,182, compared to total revenues of $299,237 for the second quarter of 2005, an increase of over 1,290%. The improved revenues and financial performance on a quarterly comparative basis have primarily resulted from the merger with RiceX and the continued success of the sale of its nutraceutical through direct to consumer marketing during quarter ended December 31, 2005. Approximately 62% of revenues in the quarter were from infomercial sales and 38% from the Company's expanded product lines and increased demand of it value added ingredients for the functional food industry and animal markets.
Total revenues for the six months ended June 30, 2006 were $7,947,726, compared to total revenues of $758,545 for the six months ended June 30, 2005, an increase of over 948%. The significant improvement in improved revenues and financial performance on a quarterly comparative basis are a culmination of the merger with RiceX, direct marketing of its expanding proprietary patented product line and sales of its core products into the functional food industry and animal markets during the quarter ended December 31, 2005.
NutraCea reported net income of $399,434 or $0.01 per share for the second quarter of 2006 based on weighted average shares outstanding of 71,791,913, compared to a net loss of $(1,800,084), or $(0.05) per share in 2005 based on 36,793,254 weighted average shares outstanding.
NutraCea had a net income of $165,860 or $0.00 per share for the six months ended June 30, 2006 based on weighted average shares outstanding of 68,808,345, compared to a net loss of $(2,664,777), or $(0.07) per share in 2005 based on 36,355,262 weighted average shares outstanding.
NutraCea reported positive earnings before interest, taxes, depreciation and amortization (EBITDA)* of $684,559 in the second quarter of 2006 compared to a negative EBITDA of $1,540,175 in the second quarter of 2005, an improvement of $2,224,734. In addition, EBITDA* for the six month period was a positive $717,452 compared to a negative EBITDA of $2,153,530 in the first six months of 2005, an improvement of $2,870,982.
*EBITDA Reconciliation
EBITDA represents net income (loss) before interest, taxes, depreciation and amortization. EBITDA is not a measurement of financial performance under accounting principles generally accepted in the United States. The following table presents EBITDA amounts for the six and three month periods ended June 30, 2006 and 2005. The table also sets forth for these periods a quantitative reconciliation of the differences between EBITDA and net income (loss), as net income (loss) is calculated in accordance with generally accepted accounting principles:
Mr. Brad Edson, President and CEO of NutraCea commented, "We are pleased to report the first profitable quarter in the Company's history and we look forward to executing on our domestic and international business models to achieve sales and profitability in both markets. Since the merger we have reported three consecutive quarters of record revenues, demonstrating our success and leadership as the world's dominant supplier of stabilized rice bran and of value-added ingredients.
Mr. Edson added, "Our expansion plans to increase production capacity of our stabilized rice bran are well underway and expected to be materially accretive to our business during the second half of this year. In this regard, we continue to ramp up revenues and fulfill existing agreements as our additional capacity comes on line, which we believe will allow us to capture more opportunities for sales and implementation of our technology around the world as we move forward. Our capital structure remains strong with no debt on the balance sheet and nearly $15 million in cash."
A conference call is scheduled for today at 11:30 a.m. EDT. Interested parties may participate in the call by dialing 877-407-8037; international callers dial 201-689-8037. In addition, the conference call will be available via a webcast that can be accessed at: http://www.vcall.com/IC/CEPage.asp?ID=107849 and will be archived for 7 days.
About NutraCea
NutraCea is a world leader in stabilized rice bran technology. Through its wholly owned subsidiary RiceX, the Company manufacturers as well as distributes products and food ingredients made from rice bran through its proprietary technology and processes. The Company has developed intellectual property to create a range of proprietary product formulations, delivery systems and whole food nutrition products. NutraCea's proprietary technology enables the creation of food and nutrition products from rice bran, normally a wasted by-product of standard rice processing. In addition to its whole foods products, NutraCea develops families of health promoting "nutraceuticals," including natural arthritic relief and cholesterol-lowering products. More information can be found in the Company's filings with the SEC and you can visit the NutraCea web site http://www.NutraCea.com .
Forward Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that any increased production capacity will be delayed or reduced in whole or in part, that some or all of the pending matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.
Company Contact: Investor Relations Contact: Margie Adelman Stephen D. Axelrod, CFA Senior V.P. NutraCea Wolfe Axelrod Weinberger Assoc, LLC 916-933-7000 Ext. 646 212-370-4500 916-220-3500 cell steve*wolfeaxelrod.com madelman*nutracea.com Media Relations Contact: Alisa D. Steinberg Wolfe Axelrod Weinberger Assoc, LLC 212-370-4500 alisa*wolfeaxelrod.com
INSIDER BUYS!!!!
08/03/2006 ADELMAN, MARGIE 11,765 B Buy 08/03/2006 EDSON, BRADLEY 11,000 B Buy 08/02/2006 NEWLAND, KODY K. 7,000 B Buy 08/02/2006 BENSOL, DAVID S. 5,000 B Buy 08/01/2006 NEWLAND, KODY K. 3,000 B Buy 07/31/2006 EDSON, BRADLEY 10,000 B Buy
Yes all these buys in recent days....Point to fwd growth..
-------------------- This is not a recommendation to buy or sell securities. Posts: 1206 | Registered: Feb 2006
| IP: Logged |
posted
I think at least 4% rise tomorrow...and thereafter!!! Anybody else have any opinion!!
INSIDER BUYS!!!!
08/03/2006 ADELMAN, MARGIE 11,765 B Buy 08/03/2006 EDSON, BRADLEY 11,000 B Buy 08/02/2006 NEWLAND, KODY K. 7,000 B Buy 08/02/2006 BENSOL, DAVID S. 5,000 B Buy 08/01/2006 NEWLAND, KODY K. 3,000 B Buy 07/31/2006 EDSON, BRADLEY 10,000 B Buy
-------------------- This is not a recommendation to buy or sell securities. Posts: 1206 | Registered: Feb 2006
| IP: Logged |
posted
Thanks for taking notice of this baby... There were some 25,000 and 30,000 block of 1.00 buys around 10:30 am...Seems like gonna form another flag here and break up... This is the time to load even more here Repoman!!
-------------------- This is not a recommendation to buy or sell securities. Posts: 1206 | Registered: Feb 2006
| IP: Logged |
posted
NutraCea Signs Seven-Year Definitive Agreement with StoneBridge Pharma LLC Tuesday September 5, 8:00 am ET -Rice Bran Fiber Gastrointestinal Products to be Distributed In Tens of Thousands of National Chain Drug Stores, Supermarkets and Mass-Market Retailers-
EL DORADO HILLS, Calif., Sept. 5 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ - News), a world leader in stabilized rice bran technology, announced today it has signed a seven-year supply and distribution agreement with StoneBridge Pharma LLC, a leading specialty pharmaceutical company. Under the agreement, StoneBridge will begin to market and distribute over-the- counter gastrointestinal products utilizing NutraCea's Rice Bran Fiber. StoneBridge customers include tens of thousands of drug stores, supermarkets and mass-market retailers nationwide. The first product to be manufactured will be Rice Bran Fiber Wafers, which will incorporate NutraCea's proprietary stabilized rice bran fiber into a delectable wafer form to provide an easy means for one to supplement their fiber intake. NutraCea will begin shipping product to StoneBridge in the fourth quarter of this year and launch nationally in retail markets in early 2007. Financial terms of the agreement were not disclosed.
Today's definitive agreement follows a Binding Letter of Intent (LOI), signed by both companies on March 29, 2006 regarding StoneBridge's right to market the all-natural, nutritional fiber product line exclusively produced and supplied by NutraCea.
"StoneBridge is an outstanding business partner, given its strong relationships with major chain drug stores, wholesalers, supermarkets, mass- market retailers, and more than 24,000 independent pharmacies around the country. We are very pleased to build on what has already become a successful supply and distribution platform for our nutritional stabilized rice bran products," said Bradley Edson, President and CEO of NutraCea.
"We believe that NutraCea's unique line of all-natural, gastrointestinal products made from fractionated rice bran will play an important role in growing the human-fiber market over the long term. The fiber market category is a multi-billion dollar annual revenue opportunity dominated by a couple of large players. We feel this product will allow us the opportunity to gain a significant footprint in this category and even give us the opportunity to become an industry leader within the next several years. Together, we anticipate expanding consumer choice, increasing market demand and carving out a meaningful share of the human-fiber market," said Robert Sykora, R.Ph., President of StoneBridge Pharma.
"Through this supply and distribution agreement consumers will now have an outstanding, natural option for supplementing essential dietary fiber to promote gastrointestinal health. Dietary rice bran fiber potentially offers several health benefits such as lowering an individual's cholesterol and helping to maintain healthy blood glucose levels," said Margie Adelman, Senior Vice President of NutraCea.
Bi-Coastal Pharmaceutical Corp., which works with NutraCea to secure agreements with pharmaceutical companies and sales and distribution arrangements for NutraCea's proprietary stabilized rice bran products and technology, was instrumental in facilitating the agreement with StoneBridge Pharma.
"I am pleased that we were able to solidify a synergistic working relationship between NutraCea and StoneBridge Pharma. The consumer is seeking natural product alternatives to stay healthy and I am confident that this collaboration will result in the successful distribution of a very beneficial natural fiber product," said Ralph Massa, Jr., Bi-Coastal Pharmaceutical's President and Chief Operating Officer.
About NutraCea
NutraCea is a world leader in stabilized rice bran technology. Through its wholly owned subsidiary RiceX, the Company manufacturers as well as distributes products and food ingredients made from rice bran through its proprietary technology and processes. The Company has developed intellectual property to create a range of proprietary product formulations, delivery systems and whole food nutrition products. NutraCea's proprietary technology enables the creation of food and nutrition products from rice bran, normally a wasted by-product of standard rice processing. In addition to its whole foods products, NutraCea develops families of health promoting "nutraceuticals," including natural arthritic relief and cholesterol-lowering products. More information can be found in the Company's filings with the SEC and you can visit the NutraCea web site at http://www.NutraCea.com.
About StoneBridge Pharma LLC
StoneBridge Pharma, a Georgia based LLC, is a specialty pharmaceutical company focused on solutions to address unmet needs that are clinically useful and financially advantageous to the patient, physician, and the Company in the areas of gastroenterology, ophthalmology, and women's health.
Since its creation, StoneBridge has cultivated a culture that values entrepreneurial zeal, innovation, market knowledge, and service excellence in order to identify the most critical healthcare issues for its market segments, develop solutions to those issues, and measurably improve the quality of healthcare.
Bi-Coastal Pharmaceutical Corp. is a diversified Sales, Marketing and Consulting company headquartered in Red Bank, New Jersey and was founded in 1982. The multi-faceted company has marketed and sold products for many well- known companies in the pharmaceutical industry such as Warrick Pharmaceutical, the generic division of Schering-Plough, and Amide Pharmaceutical. For more information on Bi-Coastal Pharmaceutical, please visit the Bi-Coastal website at http://www.bicoastalpharm.com.
Forward Looking Statements
-------------------- Stick with Repo's plan in '07 - FRPT/DKAM! Posts: 6379 | From: PA | Registered: Dec 2004
| IP: Logged |
posted
I'm in at 1.38. Should have bought in the .90's, but if you look at insider transactions, insiders are buying in the 1.20's still. Last quarter's financials were awesome, and they presented at the Roth Conference. I think over the coming weeks, this stock will slowly creep up to next financials. It is overlooked at this point.
-------------------- Stick with Repo's plan in '07 - FRPT/DKAM! Posts: 6379 | From: PA | Registered: Dec 2004
| IP: Logged |
NutraCea Announces Record Third Quarter Results Tuesday November 14, 5:25 pm ET - Company Reports Record Gross Revenue and Record Net Income -
EL DORADO HILLS, Calif., Nov. 14 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ - News), a world leader in stabilized rice bran research and technology, announced today record financial results and a record profit for its third quarter and nine months ending September 30, 2006, marking the third consecutive quarter of record results.
Total revenues for the three months ended September 30, 2006 were $4,946,174, compared to total revenues of $301,726 for the third quarter of 2005, an increase of over 1,639%. The improved revenues and financial performance on a quarterly comparative basis have primarily resulted from the merger with RiceX and the continued strength of the direct-to-consumer marketing of its nutraceutical products through the quarter ended September 30, 2006. Infomercial sales remained strong and the Company continued to experience growth from its expanded product lines and increased demand of its value-added ingredients for the functional food industry and animal markets.
Total revenues for the nine months ended September 30, 2006 were $12,893,900, compared to total revenues of $1,060,271 for the nine months ended September 30, 2005, an increase of over 1,216%. The significant improvement in revenues and financial performance for the nine months ended September 30, 2006 is the result of the culmination of the merger with RiceX, direct marketing of its expanding proprietary, patented product line and sales of its core products into the functional food industry and animal markets and continued growth in sales of nutraceutical products through direct-to-consumer marketing.
NutraCea reported net income of $641,106 or $0.01 per share for the third quarter of 2006 based on weighted average shares outstanding of 77,377,010, compared to a net loss of $(1,035,544), or $(0.03) per share in 2005 based on 38,033,352 weighted average shares outstanding. NutraCea had a net income of $806,971 or $0.01 per share for the nine months ended September 30, 2006 based on weighted average shares outstanding of 71,685,402, compared to a net loss of $(3,711,245), or $(0.10) per share in 2005 based on 36,756,797 weighted average shares outstanding.
Mr. Brad Edson, President and CEO of NutraCea commented, "We are delighted to report our third consecutive record quarter notwithstanding substantial expenditures in the most recent quarter that were necessary to meet strategic plans to realize continuing growth for the year 2007 and beyond. These expenditures included the addition of highly qualified personnel from the domestic and international food category, as well as the implementation of financial oversight processes to achieve and maintain 404 Compliance and other essential general and administrative expenses. In this quarter we accomplished many of our current business goals, including expanding our production capacity and entered into two new licensing agreements for the use of our formulations in specific channels of distribution. We believe there will be additional strategic agreements and licensing opportunities of equal and potentially greater size in the future. In the ensuing quarters, based on initiatives already underway, we anticipate sustainable positive financial results."
Mr. Edson added, "Several of our planned expansions are either completed or in the final phases of completion. By this time next year the Company is planning to have five plants operational, bringing our total capacity to produce stabilized rice bran to over 70,000 tons per year, compared to a production capacity of less than 10,000 tons per year at the beginning of 2006. We feel confident that there is a very substantial global demand for stabilized rice bran and we intend to explore all potential initiatives to further satisfy that demand."
"Having already obtained significant market demand in the United States," Mr. Edson concluded. "We're focusing on opportunities to extend our reach into other parts of the world and duplicate our U.S. success elsewhere. All of our existing or planned production facilities have been completely financed out of funds already raised and from our cash flow. At the end of the third quarter, the Company remains debt free with cash on hand and marketable securities amounting to $13.4 million. In addition, several million dollars have been added to our balance sheet since the end of the 3rd quarter from the exercise of warrants, which will be reflected in our fourth quarter numbers. We are looking forward to aggressively pursuing and executing on many diverse opportunities that exist worldwide. "
A conference call is scheduled for Wednesday, November 15, at 11:30 a.m. EST. Interested parties may participate in the call by dialing (877) 407-8037; international callers dial (201) 689-8037. In addition, the conference call will be available via a web cast that can be accessed at: http://www.vcall.com/IC/CEPage.asp?ID=111209 and will be archived for 30 days.
-------------------- Stick with Repo's plan in '07 - FRPT/DKAM! Posts: 6379 | From: PA | Registered: Dec 2004
| IP: Logged |
posted
NutraCea Receives Purchase Order From Pronaca for Stabilized Rice Bran and Solubles Tuesday November 28, 8:00 am ET Largest Food Company in Ecuador Advances Research and Development of Stabilized Rice Bran Products for Commercial Development
EL DORADO HILLS, Calif., Nov. 28 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ - News), a world leader in stabilized rice bran research and technology announced today that Pronaca, the largest food producer in Ecuador, has placed its second and more significant order for product, pursuant to its agreement signed with NutraCea in May of this year.
The order, which was shipped this week, is to meet the extensive and continuing product development work and commercial test marketing that Pronaca has been undertaking over the last several months, as a pre-curser to an anticipated full commercial roll out in mid 2007. As detailed in our Sales and Distribution agreement, signed earlier in 2006, Pronaca is pursuing an initial test product development, and market study for the commercialization of various products utilizing NutraCea's stabilized rice bran, both as a stand alone ingredient in animal and food products as well as utilization of Solubles, the higher level fraction as part of finished drinks and ingredient additives for finished products.
"In accordance with the Supply and Marketing Agreement NutraCea signed with Pronaca this shipment complies with the milestone markers for continuation of our agreement and confirms the commitments of the parties to move towards more substantial economic milestones and ultimately mass product roll-out utilizing Pronaca's food distribution system in Ecuador, which is the largest in the country, as well as elsewhere in South America. We feel this shipment will broaden the demand for our products not only in Ecuador, but throughout South America," said Margie Adelman, Senior Vice President of NutraCea.
"We are very eager to receive this shipment of product, which will enable us to move forward with our original plan to explore a variety of uses for NutraCea's products as a value added food ingredient, enhancing Pronaca's livestock and aquaculture projects, and introduction of the products into retail as well as government sponsored feeding programs," said Patricio Calderon, Manager of Rice Business for Pronaca.
"We are very pleased to be partners with Pronaca, which has been in business for more than 40 years, has over 7000 employees and is the largest commercial food producer in Ecuador, with distribution of its products in Brazil, Colombia and Peru. This purchase order demonstrates a firm commitment from Pronaca to advance our mutual interests and we offer our continued support for a successful future product launch in Ecuador and throughout Latin America in 2007," said Brad Edson, President and CEO of NutraCea.
-------------------- Stick with Repo's plan in '07 - FRPT/DKAM! Posts: 6379 | From: PA | Registered: Dec 2004
| IP: Logged |
Eye on NutraCea: A Radically Undervalued Smallcap Stock Monday February 12, 4:24 am ET
Thomas Kelly submits: I've just finished poring over everything I could get my hands on about Nutracea and I am incredibly impressed with this company. In particular, I think that CEO Brad Edson really knows what he is doing. He gives some of the most detailed and informative conference calls I've ever heard. ADVERTISEMENT
I'm going to draw from a number of sources and give you the basic file on NTRZ, and then create my own earnings estimates and do some valuation analysis. I wish I could give you all of my notes regarding the company, but they are probably too long to keep your attention. I highly encourage individual investors to go beyond the information listed here in order to understand NTRZ's Stage I and II plant structure, pricing, etc. In particular, the following PDF file, a presentation given by the CEO in September, contains a wealth of excellent information.
Profile
NutraCea, a health science company, engages in the development and distribution of stabilized rice bran and rice bran-based products for the consumer food and animal feed sectors. Nutracea's patent protected, proprietary technology allows it to stabilize rice bran, the most nutricious part of the rice kernel. (Before NTRZ, rice bran was a virtually worthless byproduct of the rice milling process. It remains very inexpensive, as it has few applications without NTRZ's technology.) It then sells this stabilized rice bran [SRB] for both human and animal consumption. Its products include food supplements and medical foods for humans and animals. Its customers include General Mills (NYSE: GIS - News), Purina, Archer Daniels Midland (NYSE: ADM - News), and several other Fortune 500 companies, as well as foreign governments in the developing world.
Market
NTRZ is the only company in the world that has the ability to create SRB. Based on the fact that 70% of the world consumes rice as their number one source of grains, the potential market is enormous. At present, NTRZ is predicted to have a capacity to create 70k tons of SRB in 2007. Current world rice production is about 60 million metric tons, so obviously, NTRZ has just begun to scratch the surface of this market.
Furthermore, NTRZ has been capacity constrained and operating at 100% capacity since 2005. They are pursuing an aggressive expansion program in order to meet the demand for SRB, which in the words of the CEO, "exceeds our production capacity many times over." NTRZ can basically sell all it can produce, and because the technology is proprietary, they have no competition.
2006 Year in Review
NTRZ has yet to report FY2006 earnings, but there is enough visibility to make estimates here. It is clear that 2006 has been an incredible year for NTRZ. They have recorded their first quarter of profitability in Q2, and will report their first full year of profitability. Based on my estimates, NTRZ should announce revenues of approximately $6.5 million for Q4, and a net income of approximately 0.02 cents per share. Full year revenues should exceed 19 million, an increase of about 300% on 2005. Meanwhile, earnings should come in at 0.03 cents per share, representing NTRZ's first year of profitability in its history.
More importantly, NTRZ has completed significant capacity expansion in 2006. They completed the expansion of their Dillon, MT plant in September of 2006, which should add some $10.8 million to revenues annually. They are also scheduled to begin production at their new plant in Louisiana in January 2007. This new plant should add another $12 million to revenues annually.
2007 Outlook
NTRZ continues to engage in expansion projects in order to meet the overwhelming demand for its products. They plan to complete another plant in the U.S. which should add $32 million in revenue annually. They are also looking at the construction of a European plant with capacity for 40k tons of SRB, or revenues of at least $16 million (assuming no stage II production).
2008 Outlook
The company has stated their desire to maximize production capability in the U.S. with 7 plants. These plants will likely be completed in 2008, giving the company a potential for greater than $150 million (possibly $250) in revenue in 2008.
Posts: 6410 | Registered: Jul 2006
| IP: Logged |
posted
hey surf, saw this news at pinksheets today,
NutraCea (OTC BB: NTRZ), a world leader in stabilized rice bran research and technology recently announced that Manna Pro, a leading manufacturing and marketing company of equine, specialty and animal nutrition feed products, will launch the highly nutritious branded equine ingredient technology, MaxEglo, to be sold at 550 of the 676 Tractor Supply Company (Nasdaq: TSCO) stores nationwide.
Posts: 81 | From: venice, fl | Registered: Aug 2006
| IP: Logged |
posted
Buy it and forget it guys..I have been in since 0.90 and refuse to sell a single share. Buy it for ur retirement. It was stock doc's very first gift to me.
-------------------- This is not a recommendation to buy or sell securities. Posts: 1206 | Registered: Feb 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
